English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background In 2018, our Trust approved the use of vedolizumab in children with Ulcerative Colitis (UC) and ustekinumab in children with Crohn’s Disease (CD). At the time, access to these drugs for children was only possible through research studies. Our aim was to assess the efficacy and safety of these novel treatments in our cohort. Methods We conducted an observational single centre cohort study. Data was obtained from our electronic system, Cerner Millennium, and Infoflex database. Analysis was performed using SPSS. Results 27 children were treated with vedolizumab or ustekinumab with 1 receiving both. All patients had failed anti-TNF medication, except 1 research patient who commenced on vedolizumab at diagnosis. Conclusion In children with refractory IBD failing anti-TNF treatment, vedolizumab and ustekinumab are effective and safe alternatives for inducing and maintaining remission, avoiding major invasive surgery.

P386 Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumab